Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
TWO:4123 Center Ventures, established in 1957, is a biotechnology investment firm based in Taiwan. Originally rooted in the pharmaceutical industry, the organization was redefined in 2008 as a 'biotechnology industrial bank' to better support promising biotech and health companies aiming for international markets. The firm has since evolved to focus on early-stage investments, particularly in the biotech and healthcare sectors.
Currently, TWO:4123 Center Ventures manages assets totaling $1 billion. The firm operates primarily within the Asian market, emphasizing its commitment to fostering innovation and entrepreneurship. Its headquarters is located in Taipei City, with additional facilities in Hsinchu County. The organization has made significant strides in nurturing startups, facilitating their growth, and helping them expand internationally.
TWO:4123 Center Ventures invests primarily in early-stage startups across various sectors, with a strong emphasis on biotechnology and healthcare. The firm targets pre-seed, seed, and seed-plus stages, providing essential resources and support to help these startups thrive. Their investment strategy includes a focus on drug development, protein and antibody drug development, health products, agricultural biotechnology, and medical devices.
The organization seeks to partner with companies that demonstrate significant growth potential and aims to facilitate their international expansion. By integrating resources and optimizing their portfolio, TWO:4123 Center Ventures strives to drive innovation and success in the biotech and healthcare industries.
TWO:4123 Center Ventures has built a notable portfolio of companies within the biotech and healthcare sectors. Key portfolio companies include:
This diverse portfolio reflects the firm's commitment to supporting innovative companies that are poised for growth in the biotech and healthcare markets.
林榮錦: Chairman. He has extensive experience in the biotechnology sector and has been instrumental in guiding the firm’s strategic direction.
許瑞寶: General Manager. He oversees the day-to-day operations and plays a key role in investment decisions.
王素琦: Honorary President. She brings a wealth of knowledge and experience in the biotech industry, contributing to the firm’s vision and strategy.
TWO:4123 Center Ventures runs a talent training camp designed to nurture young professionals in the biotech industry. This program is open to university and graduate students, offering internships across various fields within the organization. Participants gain hands-on experience and insights into the biotech sector, preparing them for future careers in the industry.
In recent months, TWO:4123 Center Ventures has continued to expand its portfolio, focusing on investments in innovative biotech startups. The firm has hosted various events aimed at connecting with young professionals in the biotech field, including training camps and investor meetings.
Additionally, the organization has published updates on its website regarding clinical trials and strategic partnerships, showcasing its commitment to supporting portfolio companies in their growth journeys.
What are the investment criteria for TWO:4123 Center Ventures?
TWO:4123 Center Ventures focuses on early-stage investments in the biotech and healthcare sectors. They look for startups with significant growth potential and innovative solutions that can address market needs.
How can I pitch my startup to TWO:4123 Center Ventures?
Founders can pitch their startups by reaching out through the official website. A well-prepared pitch deck that outlines the business model, market opportunity, and team is essential.
What makes TWO:4123 Center Ventures different from other investors?
The firm specializes in biotech and healthcare investments, leveraging its extensive industry experience and resources to support startups in these sectors. Their focus on nurturing companies for international expansion sets them apart.
What is the geographic scope of TWO:4123 Center Ventures?
The firm primarily operates in the Asian market, focusing on startups based in Taiwan and other Asian countries.
What is the typical check size for investments?
While specific check sizes are not disclosed, TWO:4123 Center Ventures invests in early-stage rounds, which typically range from pre-seed to seed-plus stages.
What kind of support do portfolio companies receive post-investment?
Portfolio companies benefit from access to resources, mentorship, and potential partnerships that can enhance their growth and facilitate international market entry.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.